Physiologically Based Pharmacokinetic Model of Brigatinib in Healthy Volunteers and Patients With Cancer
{{output}}
Brigatinib, an oral ALK inhibitor for metastatic NSCLC, lacks dosing guidance for special populations such as the Chinese. This study developed a physiologically based pharmacokinetic (PBPK) model using European data from patients with hepatic/renal impairment... ...
